Mefruside

Summary

Mefruside (CHEMBL2105131) is an approved small molecule (ATC C03BA05); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03BA05
• Indications: 1 condition
• Chemistry: 382.9 Da · C13H19ClN2O5S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105131
Name	Mefruside
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4047
ATC	C03BA05
Molecular formula	C13H19ClN2O5S2
Molecular weight	382.9
InChIKey	SMNOERSLNYGGOU-UHFFFAOYSA-N

SMILES: CC1(CCCO1)CN(C)S(=O)(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N

IUPAC name: 4-chloro-1-N-methyl-1-N-[(2-methyloxolan-2-yl)methyl]benzene-1,3-disulfonamide

Also known as: BAY 1500, BAY-1500, Baycaron, Mefrusida, Mefruside, MEFRUSIDE, SID144206878, mefruside

Patent coverage: 1,235 distinct patent families (5,040 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).